Active Ingredient(s): Cabozantinib (S)-Malate
FDA Approved: * April 25, 2016
Pharm Company: * EXELIXIS INC
Category: Cancer

Cabozantinib, sold under the brand names Cometriq and Cabometyx among others, is a medication used to treat medullary thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma. It is a small molecule inhibitor of the tyrosine kinases c-Met and VEGFR2, and also inhibits AXL and RET. It was discovered and developed by Exelixis Inc. In November 2012, cabozantinib in its capsule formulation was approved by the U.S. Food and Drug Administration (FDA) under the name Cometriq for treating ... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Cabometyx 60 mg Oral Tablet
NDC: 42388-023
Exelixis, Inc.
Cabometyx 20 mg Oral Tablet
NDC: 42388-024
Exelixis, Inc.
Cabometyx 40 mg Oral Tablet
NDC: 42388-025
Exelixis, Inc.

Related Brands

Drugs with the same active ingredients